Qiyu Bio

Qiyu Bio is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the development of innovative multi-specific antibody therapies. The company utilizes its proprietary Q-Bi and Q-Tri platforms to design and engineer bispecific and trispecific antibodies that target complex disease pathways in oncology and autoimmune disorders. Its lead asset, Q-1802, is a bispecific antibody targeting Claudin 18.2 and PD-L1, currently in Phase 2 clinical trials for gastric and pancreatic cancers. Another key program, Q-1801, targets the SIRPα/PD-L1 pathway to enhance innate and adaptive immune responses against solid tumors. Qiyu Bio focuses on creating first-in-class biologics with enhanced therapeutic windows and improved patient outcomes. The company is backed by prominent life science investors and led by a management team with deep expertise in antibody engineering and clinical development.